Context Therapeutics Inc. (CNTX) AI Stock Summary

Snapshot

Context Therapeutics is a clinical-stage biotech focused on cancer treatments that currently generates no revenue and burns through cash to fund research. The company lost $36.1M in FY 2025 and holds $43.0M in cash as of the latest update, giving it a tight runway of about 14 months. Shareholders have seen significant dilution, with the share count increasing 63% in the past year to support these operations.

What's Happening Right Now

• Mon 6th Jul '26 · Index Inclusion: Context Therapeutics was added to the Russell 2000 and Russell 3000 indexes, a move that typically brings passive investment inflows from index funds.
• Mon 15th Jun '26 · Clinical Data: Context Therapeutics reported positive interim Phase 1 data for CTIM-76 in ovarian cancer patients, showing a 29% confirmed overall response rate and a favorable safety profile.
• Mon 18th May '26 · Licensing Deal: Context Therapeutics amended its license with BioAtla to buy out future milestone and royalty obligations for CT-202 in exchange for a $6.5 million payment.

Ownership

Institutions hold 94.2% of shares, while insiders own 0.1%.

Bottom Line

This is a high-risk, pre-revenue bet on clinical trial success. The positive Phase 1 data for CTIM-76 is a real step forward, but the financial picture is strained. With a 14-month cash runway and a history of heavy dilution, investors are betting that upcoming trial results will be strong enough to justify the cost before the money runs out.